NASDAQ:DYN Dyne Therapeutics Q3 2023 Earnings Report $14.46 -0.11 (-0.75%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Dyne Therapeutics EPS ResultsActual EPS-$0.99Consensus EPS -$0.83Beat/MissMissed by -$0.16One Year Ago EPSN/ADyne Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADyne Therapeutics Announcement DetailsQuarterQ3 2023Date10/30/2023TimeN/AConference Call DateMonday, October 30, 2023Conference Call Time8:00AM ETUpcoming EarningsDyne Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dyne Therapeutics Earnings HeadlinesRaymond James bullish on biotech firms on favorable valuationJune 12 at 1:00 AM | in.investing.comDyne Therapeutics officer sells shares worth $1,949June 8, 2025 | investing.comGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 12, 2025 | Brownstone Research (Ad)US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugsJune 5, 2025 | msn.comDyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research CongressJune 5, 2025 | globenewswire.comOppenheimer Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)June 4, 2025 | americanbankingnews.comSee More Dyne Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email. Email Address About Dyne TherapeuticsDyne Therapeutics (NASDAQ:DYN), a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.View Dyne Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Wells Fargo & Company (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
